IntegraGen SA (ALINT.PA)
EUR 0.53
(0.0%)
EUR 0.53
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -709.74 Thousand EUR | 9.89% |
| 2022 | -787.64 Thousand EUR | 19.93% |
| 2021 | -983.72 Thousand EUR | -198.74% |
| 2020 | 996.27 Thousand EUR | 138.83% |
| 2019 | -2.56 Million EUR | -489.83% |
| 2018 | -435.01 Thousand EUR | 67.59% |
| 2017 | -1.34 Million EUR | -144.54% |
| 2016 | -548.94 Thousand EUR | 62.83% |
| 2015 | -1.47 Million EUR | -116.24% |
| 2014 | -682.87 Thousand EUR | -53.61% |
| 2013 | -444.55 Thousand EUR | -38.32% |
| 2012 | -321.4 Thousand EUR | -135.3% |
| 2011 | 910.56 Thousand EUR | 611.69% |
| 2010 | -177.95 Thousand EUR | 48.76% |
| 2009 | -347.29 Thousand EUR | -600.0% |
| 2008 | -49.61 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.03 Million EUR | 0.0% |
| 2023 Q2 | -856.95 Thousand EUR | 0.0% |
| 2023 FY | -709.74 Thousand EUR | 9.89% |
| 2023 Q4 | -709.74 Thousand EUR | 0.0% |
| 2022 Q4 | -787.64 Thousand EUR | 0.0% |
| 2022 Q2 | 1.04 Million EUR | 0.0% |
| 2022 FY | -787.64 Thousand EUR | 19.93% |
| 2021 Q4 | -2.82 Million EUR | 0.0% |
| 2021 FY | -983.72 Thousand EUR | -198.74% |
| 2021 Q2 | -2.28 Million EUR | 0.0% |
| 2020 FY | 996.27 Thousand EUR | 138.83% |
| 2020 Q2 | 862.1 Thousand EUR | 0.0% |
| 2020 Q4 | 996.27 Thousand EUR | 0.0% |
| 2019 Q4 | -2.56 Million EUR | 0.0% |
| 2019 Q2 | -301.48 Thousand EUR | 0.0% |
| 2019 FY | -2.56 Million EUR | -489.83% |
| 2018 Q2 | -93.04 Thousand EUR | 0.0% |
| 2018 FY | -435.01 Thousand EUR | 67.59% |
| 2018 Q4 | -435.01 Thousand EUR | 0.0% |
| 2017 Q2 | -281.75 Thousand EUR | 0.0% |
| 2017 FY | -1.34 Million EUR | -144.54% |
| 2017 Q4 | -1.34 Million EUR | 0.0% |
| 2016 Q2 | -3.77 Million EUR | 0.0% |
| 2016 Q4 | -548.94 Thousand EUR | 0.0% |
| 2016 FY | -548.94 Thousand EUR | 62.83% |
| 2015 Q2 | -4.04 Million EUR | 0.0% |
| 2015 FY | -1.47 Million EUR | -116.24% |
| 2015 Q4 | -1.47 Million EUR | 0.0% |
| 2014 Q4 | -682.87 Thousand EUR | 0.0% |
| 2014 FY | -682.87 Thousand EUR | -53.61% |
| 2014 Q2 | -5.84 Million EUR | 0.0% |
| 2013 Q4 | -444.55 Thousand EUR | 0.0% |
| 2013 FY | -444.55 Thousand EUR | -38.32% |
| 2013 Q2 | -401.14 Thousand EUR | 0.0% |
| 2012 Q4 | -321.4 Thousand EUR | 0.0% |
| 2012 Q2 | 1.54 Million EUR | 0.0% |
| 2012 FY | -321.4 Thousand EUR | -135.3% |
| 2011 FY | 910.56 Thousand EUR | 611.69% |
| 2011 Q2 | -204.62 Thousand EUR | 0.0% |
| 2011 Q4 | 910.56 Thousand EUR | 0.0% |
| 2010 Q4 | -177.95 Thousand EUR | 0.0% |
| 2010 FY | -177.95 Thousand EUR | 48.76% |
| 2010 Q2 | 400.26 Thousand EUR | 0.0% |
| 2009 FY | -347.29 Thousand EUR | -600.0% |
| 2008 FY | -49.61 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 0.595% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 99.639% |
| Adocia SA | 127 Thousand EUR | 658.857% |
| Aelis Farma SA | -16.19 Million EUR | 95.617% |
| Biophytis S.A. | 2.7 Million EUR | 126.258% |
| Advicenne S.A. | 12.17 Million EUR | 105.83% |
| genOway Société anonyme | 2.97 Million EUR | 123.873% |
| Medesis Pharma S.A. | 1.15 Million EUR | 161.28% |
| Neovacs S.A. | -237.08 Thousand EUR | -199.362% |
| NFL Biosciences SA | -2.27 Million EUR | 68.814% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 116.292% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 14.544% |
| Sensorion SA | 1.37 Million EUR | 151.497% |
| Theranexus Société Anonyme | 2.44 Million EUR | 129.039% |
| TME Pharma N.V. | -1.07 Million EUR | 34.222% |
| Valbiotis SA | -18.13 Million EUR | 96.087% |
| TheraVet SA | 12.78 Thousand EUR | 5651.42% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 132.557% |
| argenx SE | -1.83 Billion EUR | 99.961% |
| BioSenic S.A. | 28.04 Million EUR | 102.531% |
| Celyad Oncology SA | -6.1 Million EUR | 88.369% |
| DBV Technologies S.A. | -114.95 Million USD | 99.383% |
| Galapagos NV | -157.2 Million EUR | 99.549% |
| Genfit S.A. | -7.61 Million EUR | 90.675% |
| GeNeuro SA | 5.91 Million EUR | 112.008% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 97.174% |
| Innate Pharma S.A. | -30.71 Million EUR | 97.689% |
| Inventiva S.A. | 10.48 Million EUR | 106.767% |
| MaaT Pharma SA | -10.2 Million EUR | 93.045% |
| MedinCell S.A. | 39.5 Million EUR | 101.797% |
| Nanobiotix S.A. | -24.71 Million EUR | 97.129% |
| Onward Medical N.V. | -12.89 Million EUR | 94.496% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 149.621% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 102.616% |
| Oxurion NV | 10.71 Million EUR | 106.627% |
| Pharming Group N.V. | 99.4 Million EUR | 100.714% |
| Poxel S.A. | 44.55 Million EUR | 101.593% |
| GenSight Biologics S.A. | 16.29 Million EUR | 104.356% |
| Transgene SA | -14.4 Million EUR | 95.074% |
| Financière de Tubize SA | 78.62 Million EUR | 100.903% |
| UCB SA | 2.17 Billion EUR | 100.033% |
| Valneva SE | 82.73 Million EUR | 100.858% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 96.168% |